BWA
PRME icon

Basecamp Wealth Advisors’s Prime Medicine PRME Stock Holding History

Basecamp Wealth Advisors’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.08K Buy
292
+5
+2% +$17 ﹤0.01% 1503
2026
Q1 		$999 Hold
287
– – ﹤0.01% 1560
2025
Q4 		$996 Buy
+287
New +$1.28K ﹤0.01% 1497

Other funds holding PRME

Alphabet Inc
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Woodline Partners
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Basecamp Wealth Advisors's PRME Position: Q2 2026 in Review

Basecamp Wealth Advisors increased its Prime Medicine (PRME) stake by 1.7% in Q2 2026, buying an estimated $17 and bringing the position to 292 shares worth $1.08K. The position accounts for ﹤0.01% of the portfolio, ranked #1503.

Basecamp Wealth Advisors first reported a position in PRME in Q4 2025 and has held it in 3 quarters since. 187 funds tracked by Wall St. Rank hold PRME as of Q2 2026.

  • Basecamp Wealth Advisors held 292 shares of Prime Medicine worth $1.08K as of Q2 2026.
  • Basecamp Wealth Advisors bought 5 Prime Medicine shares in Q2 2026, an estimated $17.
  • Prime Medicine made up ﹤0.01% of Basecamp Wealth Advisors's portfolio in Q2 2026, its #1503 holding.
  • Basecamp Wealth Advisors first reported a position in Prime Medicine in Q4 2025 and has held it in 3 quarters since.
  • 187 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.

Based on Basecamp Wealth Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.